

## Format for ANSWERING REVIEWERS

December 04, 2014



Dear Editor,

Please find enclosed the edited manuscript in Word format (file name: Amerevised14621.doc).

**Title:** The gastric cancer and the epoch of immunotherapy approaches

**Author:** Elena Niccolai, Antonio Taddei, Domenico Prisco and Amedeo Amedei\*§

**Name of Journal:** *World Journal of Gastroenterology*

**ESPS Manuscript NO:** 14621

The manuscript has been improved according to the suggestions of reviewers:

1 Format has been updated

2 Revision has been made according to the suggestions of the reviewer

*C.1. Cancer immunotherapy has been selected as “breakthrough of the year 2013” by Science magazine. The applications of CAR T cells for adoptive T cell transfer and blockade of immune checkpoints (CTAL-4, PD-1 and LAG-3, etc.) represent the breakthrough of immunotherapy for cancer. In fact, the most commonly used approach to inhibit the immune checkpoints is to use monoclonal antibodies, the reagents on which the authors have discussed extensively for other purposes. I understand that little, if any, work has been done with gastric cancer using either of these two approaches. However, they represent valid future directions for immunotherapy of gastric cancer as well, and thus need to be discussed, albeit briefly. The short discussion on these two areas can be integrated into “Future Directions”. In this aspect, the authors may refer to a review published in this journal earlier this year: Matsueda S, Graham DY. Immunotherapy in gastric cancer. World J Gastroenterol. 2014; 20:1657-66.*

**R.1. In agreement to the Reviewer, we have discussed the approach to inhibit the immune checkpoints by using monoclonal antibodies in the section of “Future Directions” (yellow highlighted text). Also, as suggested, we have added the reference of Matsueda.. “Immunotherapy in gastric cancer” and also two new references (see references: 149,150,151)**

*C.2. Abstract, the last sentence: “...while in the second part we analyze the cell-based anti-GC treatments”. Please be more specific, and change it to ““...while in the second part we analyze the cell-based immunotherapies.”*

**R.2. As suggested by the Reviewer, we have changed the last sentence of the abstract (yellow highlighted text)**

*C.3. Monoclonal antibodies (moAbs) ...” and thereafter in the manuscript. The short name for monoclonal antibodies in the literature is “mAb” or “moAb”. Please delete the “s” in the “moAbs” (throughout the manuscript).*

**R.3. In agreement to the Reviewer, we have deleted the “s” in the moAbs abbreviation present in**

**all the text.**

**C.4** *The first line. "Du and coll." (and other similar citations) It should be "Du and colleagues". I have not read a paper in which the word "colleagues" has been shortened in such a way.*

**R.4.** **As suggested by the Reviewer, in the manuscript we have replaced the word "coll" with the word "colleagues"**

**C.5** *Figure 1. In the immune system, there are two arms, "innate immune system" (that is non-specific) and "adaptive immune system" (which is specific). Thus, please change "specific immune mechanisms" (at the top of the drawing) to "adaptive immune mechanisms", the latter of which is in parallel to "innate immune mechanisms" shown at the bottom.*

**R.5.** **By agreeing to the Reviewer, in the Figure 1 we have changed the "specific immune mechanisms" to "adaptive immune mechanisms"**

3 References and typesetting were corrected

Thank you again for publishing our manuscript in the *World Journal of Gastroenterology*.

Sincerely yours,



-----  
Dr. Amedeo Amedei

Department of Experimental and Clinical Medicine  
Section of Internal Medicine -Immunology Division  
University of Florence (P.IVA | Cod. Fis. 01279680480)  
Viale Pieraccini, 6 50134 Firenze  
Tel/Fax: + 39 055 4271495  
Mail: [aamedei@unifi.it](mailto:aamedei@unifi.it)  
Sito Web: [www.dmsc.unifi.it](http://www.dmsc.unifi.it)